Methylation of Bone SOST, Its mRNA, and Serum Sclerostin Levels Correlate Strongly With Fracture Risk in Postmenopausal Women

Inhibition of sclerostin, a glycoprotein secreted by osteocytes, offers a new therapeutic paradigm for treatment of osteoporosis (OP) through its critical role as Wnt/catenin signaling regulator. This study describes the epigenetic regulation of SOST expression in bone biopsies of postmenopausal women. We correlated serum sclerostin to bone mineral density (BMD), fractures, and bone remodeling parameters, and related these findings to epigenetic and genetic disease mechanisms. Serum sclerostin and bone remodeling biomarkers were measured in two postmenopausal groups: healthy (BMD T‐score > –1) and established OP (BMD T‐score < –2.5, with at least one low‐energy fracture). Bone specimens were used to analyze SOST mRNAs, single nucleotide polymorphisms (SNPs), and DNA methylation changes. The SOST gene promoter region showed increased CpG methylation in OP patients (n = 4) compared to age and body mass index (BMI) balanced controls (n = 4) (80.5% versus 63.2%, p = 0.0001) with replication in independent cohorts (n = 27 and n = 36, respectively). Serum sclerostin and bone SOST mRNA expression correlated positively with age‐adjusted and BMI‐adjusted total hip BMD (r = 0.47 and r = 0.43, respectively; both p < 0.0005), and inversely to serum bone turnover markers. Five SNPs, one of which replicates in an independent population‐based genomewide association study (GWAS), showed association with serum sclerostin or SOST mRNA levels under an additive model (p = 0.0016 to 0.0079). Genetic and epigenetic changes in SOST influence its bone mRNA expression and serum sclerostin levels in postmenopausal women. The observations suggest that increased SOST promoter methylation seen in OP is a compensatory counteracting mechanism, which lowers serum sclerostin concentrations and reduces inhibition of Wnt signaling in an attempt to promote bone formation. © 2014 American Society for Bone and Mineral Research.

[1]  T. Pieber,et al.  Sclerostin in Institutionalized Elderly Women: Associations with Quantitative Bone Ultrasound, Bone Turnover, Fractures, and Mortality , 2014, Journal of the American Geriatrics Society.

[2]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[3]  P. Gluckman,et al.  Childhood Bone Mineral Content Is Associated With Methylation Status of the RXRA Promoter at Birth , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  B. Dawson-Hughes,et al.  Serum sclerostin levels vary with season. , 2014, The Journal of clinical endocrinology and metabolism.

[5]  Jenneke Klein-Nulend,et al.  Nitric Oxide is Involved in the Down-regulation of SOST Expression Induced by Mechanical Loading , 2013, Calcified Tissue International.

[6]  T. Ideker,et al.  Genome-wide methylation profiles reveal quantitative views of human aging rates. , 2013, Molecular cell.

[7]  Francesco Marabita,et al.  A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data , 2012, Bioinform..

[8]  R. Chapurlat,et al.  Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study , 2013, Osteoporosis International.

[9]  S. Mousa,et al.  High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: The center of excellence for osteoporosis research study , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  W. Richards,et al.  Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. , 2012, Endocrine reviews.

[11]  Daniel L. Koller,et al.  Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture , 2012, Nature Genetics.

[12]  M. Fraga,et al.  DNA methylation contributes to the regulation of sclerostin expression in human osteocytes , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  S. Cummings,et al.  Serum sclerostin and risk of hip fracture in older Caucasian women. , 2012, The Journal of clinical endocrinology and metabolism.

[14]  Jennifer J Westendorf,et al.  Update on Wnt signaling in bone cell biology and bone disease. , 2012, Gene.

[15]  P. Gluckman,et al.  Evaluation of Methylation Status of the eNOS Promoter at Birth in Relation to Childhood Bone Mineral Content , 2012, Calcified Tissue International.

[16]  A. Rouzi,et al.  Determinants of serum sclerostin in healthy pre‐ and postmenopausal women , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  K. Toulis,et al.  Role of wingless tail signaling pathway in osteoporosis: an update of current knowledge , 2011, Current opinion in endocrinology, diabetes, and obesity.

[18]  M. Arfan Ikram,et al.  The Rotterdam Study: 2012 objectives and design update , 2011, European journal of epidemiology.

[19]  J. Riancho,et al.  Osteocyte Deficiency in Hip Fractures , 2011, Calcified Tissue International.

[20]  A. Frigessi,et al.  Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  L. Melton,et al.  Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  S. Polyzos,et al.  Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide , 2011, Osteoporosis International.

[23]  S. Reppe,et al.  Skeletal Site-Related Variation in Human Trabecular Bone Transcriptome and Signaling , 2010, PloS one.

[24]  Gerhard Hawa,et al.  Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. , 2010, The Journal of clinical endocrinology and metabolism.

[25]  Marit Holden,et al.  Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. , 2010, Bone.

[26]  R. Bhat,et al.  Wnt3‐frizzled 1 chimera as a model to study canonical Wnt signaling , 2009, Journal of cellular biochemistry.

[27]  Tobias A. Knoch,et al.  GRIMP: a web- and grid-based tool for high-speed analysis of large-scale genome-wide association using imputed data , 2009, Bioinform..

[28]  Qing-yang Huang,et al.  The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. , 2009, Bone.

[29]  Monique M. B. Breteler,et al.  The Rotterdam Study: 2016 objectives and design update , 2015, European Journal of Epidemiology.

[30]  P. Kostenuik,et al.  Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  L. Bonewald.  Osteocytes as Dynamic Multifunctional Cells , 2007, Annals of the New York Academy of Sciences.

[32]  P. Collas,et al.  Stable CpG hypomethylation of adipogenic promoters in freshly isolated, cultured, and differentiated mesenchymal stem cells from adipose tissue. , 2006, Molecular biology of the cell.

[33]  Scott Taylor,et al.  Cbfa1/RUNX2 Directs Specific Expression of the Sclerosteosis Gene (SOST)* , 2004, Journal of Biological Chemistry.

[34]  D. Galas,et al.  A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. , 2002, American journal of medical genetics.

[35]  K. Lindpaintner,et al.  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease , 2002, Journal of medical genetics.

[36]  D. Galas,et al.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. , 2001, American journal of human genetics.

[37]  M Dioszegi,et al.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.

[38]  J. Nathans,et al.  A Member of the Frizzled Protein Family Mediating Axis Induction by Wnt-5A , 1997, Science.

[39]  C. Hsieh,et al.  Dependence of transcriptional repression on CpG methylation density , 1994, Molecular and cellular biology.